Skip to main content
padlock icon - secure page this page is secure

Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia

Buy Article:

$52.00 + tax (Refund Policy)

Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D'Amico MR, Del Vecchio L, Ferrara F. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.

Eur J Haematol 2003: 71: 23–28. © Blackwell Munksgaard 2003. Abstract: Objectives:

Therapeutic results in advanced chronic lymphocytic leukemia (CLL) are still unsatisfactory in terms of complete remission achievement and duration, in spite of the extensive use of purine analogs. The objective of this study was to describe the clinical characteristics and treatment results from a series of 32 patients managed with a therapeutic program based on the combination of fludarabine and cyclophosphamide (CTX). Methods:

Thirty-two patients (median age 63 yr, range 42–75 yr) with newly diagnosed (47%) or refractory-relapsed (53%) CLL were programmed to receive six courses of a 3-d combination of fludarabine at 30 mg/m2/d plus CTX at 300 mg/m2/d. Refractory-relapsed patients had previously received different chemotherapy lines from 1 to 5. Results:

Fourteen of 32 (44%) patients achieved a complete remission, 16 (50%) obtained partial remission and two (6%) failed to respond. The CR rate was higher in untreated patients; in particular, CR was achieved in nine of 15 (60%) newly diagnosed cases as opposed to five of 17 (29%) among pretreated patients. Toxicity was caused by myelosuppression and/or infections in most cases. After a median follow-up of 24 months (range 8–48 months), 20 of 32 patients (62%) are alive, and 14 of 32 (44%) are free from progression. Median overall survival and median time to progression were 35 and 25 months, respectively. Conclusion:

The combination of fludarabine with CTX is effective in advanced CLL with acceptable toxicity, either as first-line therapy or in refractory-relapsed patients. In particular, a considerable rate of complete remission can be achieved in untreated patients. Myelosuppression represents the major side-effect.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: advanced stage; chronic lymphocytic leukemia; cyclophosphamide; fludarabine

Document Type: Research Article

Affiliations: Division of Hematology and Stem Cell Transplantation Unit,

Publication date: July 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more